Necrosis has been a profound hurdle in the treatment of chronic disease, as well as in fields such as tissue engineering, organ preservation and beyond. Our Anti-Necrotics™ hold the potential to revolutionize these fields. Our data (independently validated by three reputed CROs) has been shown to block necrosis by an unprecedented 90%.
Additionally, we are advancing several exploratory programs in senescent cells, oncology, microbiome-drug interaction, and inflammatory bowel disease. These programs leverage our Blueprint Maps to identify novel targets.
Anti-Necrotics™: Clinical Pipeline
By age 75, half of all people will have some form of kidney disease. Despite being the 9th leading cause of death worldwide (WHO)—and even the top risk for astronauts—it remains a major unmet medical need, with no drugs currently able to block the acute tubular necrosis that drives kidney disease. LINK-001 is designed as a first-in-class therapy that targets kidney disease at its core (i.e., acute tubular necrosis), positioning it as a potentially transformative therapeutic for patients who might otherwise face dialysis or transplant.
The kidney ages faster than other organs and mirrors universal aging pathways, providing a clear, well-understood mechanism and an indication where clinical trials can be completed in under two years—making kidney disease the optimal first path to regulatory approval for an aging-targeted drug.
Anti-Necrotics™: Non-Clinical Pipeline
Necrosis in cell culture imposes significant costs on optimizing media to sustain primary cells for R&D. Our Anti-Necrotics™ will enable the harvesting and extended viability of a broader range of primary cells, thereby driving innovation forward and significantly reducing costs. The cell culture media market is rapidly growing and projected to reach $13.0 billion by 2028.
Necrotic cores have long been the major obstacle in tissue engineering. Our Anti-Necrotics™ promise to overcome this challenge, enabling the growth of complex lab-grown tissues and organs for the first time. This innovation could revolutionize treatments for bowel conditions, provide replacement organs, and support space missions, ushering in a new era of bioengineered tissues and organs.
Our Anti-Necrotics could transform organ transplantation by significantly extending preservation windows. This breakthrough addresses the critical issue of organ shortages: 17 daily deaths in the U.S. alone and a new addition to the transplant waiting list every 9 minutes, offering new hope to countless patients.
